|
 |
Kaubanduslikud nimed erinevates maades |
|
|
Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist
|
|
Adwigmine |
Egiptus |
|
Amostigmine |
Egiptus |
|
Beemine |
India |
|
Epistigmine |
Egiptus |
|
Fadastigmina |
Argentiina |
|
Ipostigmine |
Iraan |
|
Miostin |
Rumeenia |
|
Neostig |
Saksamaa |
|
Neostigmin |
Rootsi, Saksamaa |
|
Neostigmina |
Argentiina, Brasiilia, Ecuador, Hispaania, Kolumbia, Maroko, Portugal, Tšiili, Venetsueela |
|
Neostigmine |
Austraalia, Egiptus, Holland, Iirimaa, Kanada, Kreeka, Malaisia, Saudi Araabia, Suurbritannia, Türgi, uus-Meremaa |
|
Normastigmin |
Austria |
|
Polstigminum |
Poola |
|
Prostigmin |
Austria, Belgia, Holland, Kreeka, Malaisia, Sveits |
|
Prostigmina |
Itaalia |
|
Prostigmine |
Araabia Ühendemiraadid, Austria, Egiptus, Hispaania, Kolumbia, Luksemburg, Maroko, Maroko, Mehhiko, Prantsusmaa, Venetsueela |
|
Setisin |
Malaisia |
|
Stigmosan |
Ungari |
|
Tigmin |
Maroko |
|
Visulmin |
Mehhiko |
|
|
 |
 |
Viited : Neostigmine methylsulfate |
|
|
tüüp |
avaldamine |
| 815 |
ajaleht |
Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL.
Stability of ondansetron hydrochloride and 12 medications in plastic syringes.
Am J Health-Syst Pharm 1998 ; 55: 2630-2634. |
| 1200 |
ajaleht |
Chaudry IA, Bruey KP, Hurlburt LE, Oden EM.
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Am J Hosp Pharm 1981 ; 38: 1737-1742. |
| 1228 |
ajaleht |
Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381. |
| 1682 |
ajaleht |
Storms M, Stewart JT, Warren FW.
Stability of neostigmine methylsulfate injection at ambient temperature and 4°C in polypropylene syringes.
Int J Pharm Compound 2002 ; 6: 475-477. |
| 2286 |
ajaleht |
Ben M, Trusley C, Kupiec TC, Trissel LA.
Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12, 4: 368-371. |
| 2291 |
ajaleht |
Yeh MK.
Degradation kinetics of neostigmine in solution.
Drug Dev Ind Pharm 2000 ; 26, 11: 1221-1226. |
| 3372 |
ajaleht |
Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166. |
| 3578 |
Labor |
Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011 |
| 3599 |
Labor |
Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics
Amco Amdipharm Mercry 2013 |
| 3644 |
Labor |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 5003 |
Labor |
NÉOSTIGMINE RENAUDIN 5 mg/5 mL, solution injectable - Résumé des caractéristiques du produit.
LABORATOIRE RENAUDIN 2019 |
|
|
